Profit

European Advisory Panel Recommends Nod For Pfizer Breast Cancer Drug

 Share
EMAIL
PRINT
COMMENTS
European Advisory Panel Recommends Nod For Pfizer Breast Cancer Drug

Pfizer shares were off slightly in premarket trading on Friday.


US drug maker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

The Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for Ibrance to be used in combination with two existing therapies in women who have received prior endocrine therapy.

The CHMP's opinion will now be reviewed by the EMA, Pfizer said in a statement on Friday.

Ibrance, approved by the US Food and Drug Administration (FDA) in February 2015, contributed about half a billion dollars of Pfizer's total revenue of $13.1 billion in its latest quarter.

Novartis is also testing an experimental breast cancer pill which belongs to same drug class as Pfizer's Ibrance. In May, tests on the drug were stopped early because of good results.

Pfizer's shares were off slightly in premarket trading on Friday.
© Thomson Reuters 2016


Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Top